HELP ▲ +2.8% - Cybin D/B/A Helus Pharma
$HELP - Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
Helus Pharma stock rose 2.8% following the company's presentation of new analyses on its HLP003 candidate for treating major depressive disorder at Psych Congress 2026. The positive clinical data presentation appears to have boosted investor confidence in the drug candidate's potential.
21-SEP-2026 07:30 AM ET
Share this post
More filings for $HELP
HELP ▲ +0.1% - Cybin D/B/A Helus PharmaOct 27, 2026HELP ▼ -2.7% - Cybin D/B/A Helus PharmaOct 21, 2026HELP ▼ -0.2% - Cybin D/B/A Helus PharmaOct 15, 2026HELP ▲ +0.4% - Cybin D/B/A Helus PharmaOct 8, 2026HELP ▲ +1.8% - Cybin D/B/A Helus PharmaOct 1, 2026HELP ▲ +1.0% - Cybin D/B/A Helus PharmaSep 22, 2026
View full $HELP filing history →💬 Comments
Loading comments…
Leave a comment
